Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 3/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | TNIK | Q9UKE5 | 4/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | ESRRB | O95718 | 1/20 | 0.39 |
| ▸ | ESRRA | P11474 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10087503 | 0.84 | TYR (0.45) | HSD17B3TTRTYRHSP90AB1GABRA1 | |
| SCHEMBL18870832 | 0.79 | TYR (0.39) | TYRLMNAHPGDHIF1AHSD17B10 | |
| SCHEMBL30979257 | 0.78 | TYR (0.48) | HSD17B3TYRHSP90AB1GABRA1GABRB2 | |
| SCHEMBL1724358 | 0.78 | TYR (0.48) | HSD17B3TYRHSP90AB1GABRA1GABRB2 | |
| SCHEMBL3570300 | 0.77 | ABAT (0.41) | TYRCYP3A4MAPTTSHR | |
| SCHEMBL26586506 | 0.77 | TYR (0.38) | TYRLMNAHPGDHIF1AHSD17B10 | |
| SCHEMBL6510330 | 0.77 | GRIN2D (0.36) | TTRGABRA1GABRB2HSD17B1ESR1 | |
| SCHEMBL28221881 | 0.77 | TYR (0.34) | TYRESR1ESR2MEN1KMT2A | |
| SCHEMBL29531568 | 0.76 | ANPEP (0.49) | HSD17B3TYRHSP90AB1GABRA1GABRB2 | |
| SCHEMBL29408416 | 0.76 | ESR1 (0.57) | TYRHSP90AB1HSD17B1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12180215-B2 | Substituted pyrrolo[3,4-d]imidazoles as JAK inhibitors | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-12-31 | — | — | US | disclosed |
| EP-3932919-B1 | JAK INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECH CO LTD (CN) | 2024-06-26 | — | — | EP | disclosed |
| US-20230201165-A1 | JAK INHIBITOR COMPOUND FOR TREATING SEVERE PNEUMONIA | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230201165-A1 | JAK INHIBITOR COMPOUND FOR TREATING SEVERE PNEUMONIA | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230201165-A1 | JAK INHIBITOR COMPOUND FOR TREATING SEVERE PNEUMONIA | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230192711-A1 | JAK INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192711-A1 | JAK INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192711-A1 | JAK INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-4186907-A1 | JAK INHIBITOR COMPOUND FOR TREATING SEVERE PNEUMONIA | Henan Medinno Pharmaceutical Technology Co., Ltd. (CN) | 2023-05-31 | — | — | EP | disclosed |
| US-11629148-B2 | Substituted pyrrolo[3,4-d]imidazoles as JAK inhibitors | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-04-18 | — | — | US | disclosed |
| CN-111606908-B | JAK inhibitor compounds and uses thereof | 河南迈英诺医药科技有限公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-111606908-A | JAK inhibitor compounds and uses thereof | 河南迈英诺医药科技有限公司 | 2020-09-01 | — | — | CN | disclosed |
| EP-1408986-B1 | PROTEOMIMETIC COMPOUNDS AND METHODS | UNIV YALE (US) | 2008-09-24 | — | — | EP | disclosed |
| US-7312246-B2 | Proteomimetic compounds and methods | YALE UNIVERSITY (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1408986-A4 | PROTEOMIMETIC COMPOUNDS AND METHODS | UNIV YALE (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050215563-A1 | Proteomimetic compounds and methods | YALE UNIVERSITY | 2005-09-29 | — | — | US | disclosed |
| US-6858600-B2 | Proteomimetic compounds and methods | YALE UNIVERSITY (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1408986-A2 | PROTEOMIMETIC COMPOUNDS AND METHODS | YALE UNIVERSITY (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030008882-A1 | Proteomimetic compounds and methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-09 | — | — | US | disclosed |
| WO-2002089738-A2 | PROTEOMIMETIC COMPOUNDS AND METHODS | YALE UNIVERSITY (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008882-A1 | Proteomimetic compounds and methods | PACSIN2, HSP90B1, PHLPP2 | HSD17B3 3620/4885TTR 138/4885TYR 4225/4885 |
| US-12180215-B2 | Substituted pyrrolo[3,4-d]imidazoles as JAK inhibitors | JAK1, JAK2, JAK3 | HSD17B3 1855/4885TTR 3184/4885TYR 367/4885 |
| US-20230192711-A1 | JAK INHIBITOR COMPOUND AND USE THEREOF | JAK2, JAK1, JAK3 | HSD17B3 2024/4885TTR 2874/4885TYR 282/4885 |
| US-20230201165-A1 | JAK INHIBITOR COMPOUND FOR TREATING SEVERE PNEUMONIA | JAK1, JAK2, JAK3 | HSD17B3 2714/4885TTR 1906/4885TYR 1696/4885 |
| US-11629148-B2 | Substituted pyrrolo[3,4-d]imidazoles as JAK inhibitors | JAK1, JAK3, JAK2 | HSD17B3 1322/4885TTR 2316/4885TYR 316/4885 |
| US-20050215563-A1 | Proteomimetic compounds and methods | PACSIN2, HSP90B1, PHLPP2 | HSD17B3 3620/4885TTR 138/4885TYR 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.